Skip to main content
CNTB
NASDAQ Life Sciences

Connect Biopharma Q3 10-Q: Going Concern Warning With $19.5M Cash and Nasdaq Bid Deficiency

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.643
Mkt Cap
$40.492M
52W Low
$0.6
52W High
$3.82
52W Position info
7.2% above low
Off High info
83% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

CNTB is trading near its 52-week low of $0.6 (7.2% above the low) on light trading volume (0.1× avg).

Summary

Connect Biopharma's Q3 10-Q carries a going-concern warning: $19.5 million of cash will not fund a year of operations, and the stock has fallen below Nasdaq's $1.00 minimum bid, triggering a deficiency letter dated November 12, 2026.


Key Events · Earnings and Guidance · CNTB

  • Going Concern Warning on $19.5M Cash

    Management states that cash, cash equivalents and short-term investments of $19.5 million at September 30, 2026 will be insufficient to meet anticipated cash requirements for at least one year from the filing date, raising substantial doubt about the ability to continue as a going concern.

  • Nasdaq Bid Price Deficiency Letter

    A November 12, 2026 Nasdaq letter flagged non-compliance with the $1.00 minimum bid price after 30 consecutive business days below it; the company has until May 11, 2027 to regain compliance with 10 consecutive closes at $1.00 or more.

  • Cash Burn Outpaces the Balance Sheet

    Nine-month net loss was $52.8 million with $44.0 million of operating cash used, versus $19.5 million of cash and investments remaining; R&D expense rose to $44.1 million from $26.5 million a year earlier on the rademikibart Phase 2 programs.

  • ATM Drip Yields Only $1.8M

    In October 2026 the company sold 1.5 million ordinary shares under its $150.0 million Cantor sales agreement for net proceeds of $1.8 million — roughly $1.20 per share — a small draw against a large remaining shelf.


Analysis · CNTB · Life Sciences

The balance sheet, not the clinical data, is now the binding constraint for Connect Biopharma. At September 30, 2026 the company held $19.5 million in cash, cash equivalents and short-term investments, and management now says that is not enough to fund operations for the next twelve months — a substantial-doubt going-concern conclusion. The burn is heavy: $44.0 million of operating cash used in the first nine months against a $52.8 million net loss. Layered on top is a November 12, 2026 Nasdaq letter flagging a minimum bid price deficiency (shares closed below $1.00 for 30 straight days), with until May 11, 2027 to regain compliance. Funding levers are limited to the $150.0 million Cantor ATM — under which it sold 1.5 million shares for just $1.8 million in October — and future equity, debt or partnership deals. The clinical story remains intact (positive Phase 2 asthma and COPD data in September, FDA meetings planned for December 2026 and Q1 2027), but the cash position now governs the outlook.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CNTB was trading at $0.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $40.5M. The 52-week trading range was $0.60 to $3.82. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CNTB - Latest Insights

CNTB
Sep 30, 2026, 7:07 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $1.03
Real-time Price: $0.619 info
Change: -$0.411 (-40%) info
Market Cap: $40.492M info
CNTB
Sep 30, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.09
Real-time Price: $0.619 info
Change: -$0.471 (-43%) info
Market Cap: $40.492M info
CNTB
Sep 15, 2026, 11:46 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $1.11
Real-time Price: $0.619 info
Change: -$0.4907 (-44%) info
Market Cap: $40.492M info
CNTB
Sep 15, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.73
Real-time Price: $0.619 info
Change: -$1.11 (-64%) info
Market Cap: $40.492M info
CNTB
Sep 15, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.9303
Real-time Price: $0.619 info
Change: -$0.3113 (-33%) info
Market Cap: $40.492M info